Back to results
US 12,295,978 B2Granted
Recombinant plasma membrane-based vesicle, for treating cancer
AssigneeShiftbio
InventorsGi-Beom Kim, Yoo Soo Yang, In-San Kim, Gihoon Nam
Life of this patent
Estimating the term…
Abstract
The present invention relates to a recombinant plasma membrane-based vesicle, and more specifically to a recombinant plasma membrane-based vesicle comprising a VSV-G mutated protein in which histidine, the 162nd amino acid, has been substituted with arginine, and a pharmaceutical composition for treating cancer comprising the recombinant plasma membrane-based vesicle.
Claims15
A method of treatment comprising administering a therapeutically effective amount of a recombinant plasma membrane-based vesicle to a subject that has cancer, wherein:
- (i) a vesicular stomatitis virus glycoprotein (VSV-G) mutated protein in which the 162nd amino acid, histidine, is substituted with arginine is introduced into the membrane of the vesicle and
- (ii) the vesicle is free of other anti-cancer agents.
Dependencies are inferred from the claim text.